Gofen & Glossberg LLC Exact Sciences Corp Transaction History

Gofen & Glossberg LLC

$3.89 Billion
Q4 2022

A detailed history of Gofen & Glossberg LLC transactions in Exact Sciences Corp stock. As of the latest transaction made, Gofen & Glossberg LLC holds 7,400 shares of EXAS stock, worth $512,153. This represents 0.01% of its overall portfolio holdings.

Number of Shares

7,400

Previous 7,400 -0.0%

Holding current value

$512,153

Previous $240,000 52.5%

% of portfolio

0.01%

Previous 0.01%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 14, 2022	BUY	$57.56 - $82.54 $40,292 - $57,778	700 Added 10.45%	7,400 $517,000
Q4 2020 Jan 15, 2021	SELL	$99.61 - $142.12 $3,087 - $4,405	-31 Reduced 0.46%	6,700 $888,000
Q3 2020 Oct 09, 2020	SELL	$72.92 - $102.01 $72,920 - $102,010	-1,000 Reduced 12.93%	6,731 $686,000
Q1 2020 Apr 14, 2020	SELL	$37.9 - $104.44 $5,685 - $15,666	-150 Reduced 1.9%	7,731 $448,000
Q4 2019 Jan 28, 2020	SELL	$77.66 - $99.74 $31,995 - $41,092	-412 Reduced 4.97%	7,881 $729,000
Q3 2019 Oct 10, 2019	BUY	$90.37 - $122.49 $1,626 - $2,204	18 Added 0.22%	8,293 $749,000
Q2 2019 Jul 12, 2019	SELL	$89.51 - $118.04 $8,951 - $11,804	-100 Reduced 1.19%	8,275 $977,000
Q1 2019 Apr 11, 2019	BUY	$61.98 - $96.5 $9,297 - $14,475	150 Added 1.82%	8,375 $725,000
Q3 2018 Oct 11, 2018	BUY	$48.29 - $80.6 $18,108 - $30,224	375 Added 4.78%	8,225 $649,000
Q1 2018 Apr 11, 2018	SELL	$39.82 - $57.53 $45,793 - $66,159	-1,150 Reduced 12.78%	7,850 $317,000
Q4 2017 Jan 11, 2018	SELL	$46.49 - $60.51 $9,298 - $12,102	-200 Reduced 2.17%	9,000 $473,000
Q2 2017 Aug 16, 2017	BUY	N/A	9,200	9,200 $325,000

Others Institutions Holding EXAS

# of Institutions

621

Shares Held

166M

Call Options Held

1.93M

Put Options Held

1.23M

View Full List

About EXACT SCIENCES CORP

Ticker EXAS
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 176,960,000
Market Cap $12.2B
Description
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...

More about EXAS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Gofen & Glossberg LLC , based on Form 13F filings with the SEC.

News

Stay updated on Gofen & Glossberg LLC with notifications on news.

Account

Gofen & Glossberg LLC Exact Sciences Corp Transaction History